Journal
TOPICS IN CURRENT CHEMISTRY
Volume 379, Issue 1, Pages -Publisher
SPRINGER INT PUBL AG
DOI: 10.1007/s41061-020-00318-2
Keywords
COVID-19; Remdesivir; Favipiravir; Chloroquine; Hydroxychloroquine; Ruxolitinib
Categories
Funding
- Natural Science Foundation of China [21676076, 21878071, 21971060]
- Hu-Xiang High Talent in Hunan Province [2018RS3042]
- Recruitment Program of China [WQ20164300353]
Ask authors/readers for more resources
COVID-19 has rapidly spread worldwide, prompting scientists to research a variety of drugs for potential anti-viral activity. Commonly used drugs include chloroquine, hydroxychloroquine, Favipiravir, and Remdesivir.
COVID-19 has broken out rapidly in nearly all countries worldwide, and has blossomed into a pandemic. Since the beginning of the spread of COVID-19, many scientists have been cooperating to study a vast array of old drugs and new clinical trial drugs to discover potent drugs with anti-COVID-19 activity, including antiviral drugs, antimalarial drugs, immunosuppressants, Chinese medicines, M-pro inhibitors, JAK inhibitors, etc. The most commonly used drugs are antiviral compounds, antimalarial drugs and JAK inhibitors. In this review, we summarize mainly the antimalarial drugs chloroquine and hydroxychloroquine, the antiviral drugs Favipiravir and Remdesivir, and JAK inhibitor Ruxolitinib, discussing their biological activities, clinical trials and synthesis progress.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available